Journals / Anatolian Current Medical Journal / 2021 / Cilt: 3 - Sayı: 2

Monocyte/HDL ratio in women with polycystic ovary syndrome and healthy controls

Pages
98–103
Publication Date
2021-04-24
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusions: In previous studies, although the importance of MHR was emphasized in predicting and preventing obesity in PCOS cases, it was concluded that this relationship was not significant in our study.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: to examine and compare various variables, especially monocyte / high-density lipoprotein cholesterol (HDL) ratio (MHR), in women with Polycystic Ovary Syndrome (PCOS) and healthy controls.
📊
Key Findings & Data:The records of a total of 259 cases, including 194 with PCOS and 65 without PCOS who had normal menstrual cycles between the ages of 18-38, were examined.
💡
Conclusion & Impact:Conclusions: In previous studies, although the importance of MHR was emphasized in predicting and preventing obesity in PCOS cases, it was concluded that this relationship was not significant in our study.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Polycystic Ovary Syndrome · Obesity · Inflammation

Abstract

Aim: to examine and compare various variables, especially monocyte / high-density lipoprotein cholesterol (HDL) ratio (MHR), in women with Polycystic Ovary Syndrome (PCOS) and healthy controls. Materials and Methods: Data of patients who applied to Adana City Training & Research Hospital Gynecology and Obstetrics Outpatient Clinic were analyzed retrospectively from the hospital database. The records of a total of 259 cases, including 194 with PCOS and 65 without PCOS who had normal menstrual cycles between the ages of 18-38, were examined. Results: When compared with the control group, the overweight/obese PCOS group was found to have higher triglyceride value. Age and neutrophil values were significantly higher, whereas red blood cell distribution width was lower in the control group compared to both PCOS groups. Weight and BMI values were significantly different for all three groups. The HDL value was detected to be significantly higher in the normoweight PCOS group compared to the overweight/obese PCOS group. Total cholesterol value was significantly higher in the overweight/obese PCOS group compared to the normoweight PCOS group. The MHR values was found to be similar in all groups. Conclusions: In previous studies, although the importance of MHR was emphasized in predicting and preventing obesity in PCOS cases, it was concluded that this relationship was not significant in our study. Although the present study has various limitations, there are few studies on this subject and our findings represent an important difference from available results, suggesting the presence of underlying variations that necessitate further studies on this subject.

🔖

Cite This Article

GÜRBÜZ, T., OKÇU, N. T., GÜNGÖR, N. D. (2021). Monocyte/HDL ratio in women with polycystic ovary syndrome and healthy controls. Anatolian Current Medical Journal, Cilt: 3 - Sayı: 2, 98–103. https://ajindex.com/articles/733833

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nature Reviews Endocrinology 2018; 14: 270
  2. Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod 2016; 31: 2841-55
  3. Cheang KI, Huszar JM, Best AM, Sharma S, Essah PA, Nestler JE. Long-term effect of metformin on metabolic parameters in the polycystic ovary syndrome. Diabetes and Vascular Disease Research 2009; 6: 110-9
  4. Randeva HS, Tan BK, Weickert MO, et al. Cardiometabolic aspects of the polycystic ovary syndrome. Endocr Rev 2012; 33: 812-41
  5. Sathyapalan T, Atkin SL. Mediators of inflammation in polycystic ovary syndrome in relation to adiposity. Mediators Inflamm 2010; 2010
  6. Wołczyński S, Zgliczyński W. Abnormalities of the menstrual cycle. Large Interna–Endocrinology 2nd edition Medical Tribune Poland, Warsaw 2012: 561-7
  7. Group REaSPCW. Revised 2003 consensus on diagnostic criteria and long‐term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41-7
  8. Kharitonenkov A, Adams AC. Inventing new medicines: the FGF21 story. Molecular metabolism 2014; 3: 221-9
  9. Bednarska S, Siejka A. The pathogenesis and treatment of polycystic ovary syndrome: What’s new. Adv Clin Exp Med 2017; 26: 359-67
  10. Patel S. Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy. The Journal of steroid biochemistry and molecular biology 2018; 182: 27-36
  11. Auffray C, Sieweke MH, Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol 2009; 27
  12. Parthasarathy S, Barnett J, Fong LG. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochimica et Biophysica Acta (BBA)-Lipids and Lipid Metabolism 1990; 1044: 275-83
  13. Westerterp M, Gourion-Arsiquaud S, Murphy AJ, et al. Regulation of hematopoietic stem and progenitor cell mobilization by cholesterol efflux pathways. Cell stem cell 2012; 11: 195-206
  14. Kaplan I, Kaplan M, Abacioglu O, Yavuz F, Saler T. Monocyte/HDL ratio predicts hypertensive complications. Bratisl Lek Listy 2020; 121: 133-6
  15. Yakar H, Kanbay A. Could monocyte level/HDL cholesterol ratio predict cardiovascular diseases in patients with COPD? Niger J Clin Pract 2020; 23: 450
  16. Sirakaya E, Duru Z, Kuçuk B, Duru N. Monocyte to high-density lipoprotein and neutrop